TY - JOUR
T1 - Polyvalent immune globulin and cytomegalovirus infection after renal transplantation
AU - Kasiske, B. L.
AU - Heim-Duthoy, K. L.
AU - Tortorice, K. L.
AU - Ney, A. L.
AU - Odland, M. D.
AU - Rao, K. V.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1989
Y1 - 1989
N2 - To determine whether polyvalent, immune globulin (IgG) prevents cytomegalovirus (CMV) infection after cadaver renal transplantation, 28 patients were randomly allocated to receive 12 weekly infusions of 500 mg/kg of IgG (n=15) or no treatment (n=13). Both groups were similar with respect to age, sex, antigen mismatches, number of diabetics, and pretransplant donor/recipient CMV antibody titers. Moderately severe CMV infections occurred in 10 (77%) of 13 control subjects compared with 8 (53%) of 15 IgG-treated patients (not significant). Among those who developed CMV infections, prophylactic IgG had no effect on the severity or duration of fever, leukopenia, or hepatic enzyme elevations. Since none of the IgG-treated patients or control subjects in this study developed life-threatening CMV complications, a beneficial effect of prophylactic IgG in the small number of patients at risk for more severe CMV infections could not be excluded. However, this investigation suggests that the routine, prophylactic administration of polyvalent IgG, to prevent or to ameliorate CMV infection in unselected cadaver renal transplant recipients, is not warranted.
AB - To determine whether polyvalent, immune globulin (IgG) prevents cytomegalovirus (CMV) infection after cadaver renal transplantation, 28 patients were randomly allocated to receive 12 weekly infusions of 500 mg/kg of IgG (n=15) or no treatment (n=13). Both groups were similar with respect to age, sex, antigen mismatches, number of diabetics, and pretransplant donor/recipient CMV antibody titers. Moderately severe CMV infections occurred in 10 (77%) of 13 control subjects compared with 8 (53%) of 15 IgG-treated patients (not significant). Among those who developed CMV infections, prophylactic IgG had no effect on the severity or duration of fever, leukopenia, or hepatic enzyme elevations. Since none of the IgG-treated patients or control subjects in this study developed life-threatening CMV complications, a beneficial effect of prophylactic IgG in the small number of patients at risk for more severe CMV infections could not be excluded. However, this investigation suggests that the routine, prophylactic administration of polyvalent IgG, to prevent or to ameliorate CMV infection in unselected cadaver renal transplant recipients, is not warranted.
UR - http://www.scopus.com/inward/record.url?scp=0024791690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024791690&partnerID=8YFLogxK
U2 - 10.1001/archinte.149.12.2733
DO - 10.1001/archinte.149.12.2733
M3 - Article
C2 - 2556978
AN - SCOPUS:0024791690
SN - 0003-9926
VL - 149
SP - 2733
EP - 2736
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 12
ER -